Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Crofelemer Oral Product
Crofelemer Product · 1 trial · 1 indication
Change in ostomy output from baseline over the entire 12-week treatment period as average weekly ostomy output at week 12.
| Arm | Type | Description |
|---|---|---|
| Crofelemer Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Crofelemer Oral Product | DRUG | Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing) |
Inclusion Criteria: 1. Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures of the trial and be willing to complete the required assessments; 2. Male and female patients aged ≥ 18 years; 3. SBS patients wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 4 | PHASE3 | Teduglutide |
| Jaguar Health, Inc. | JAGX | 1 | PHASE2 | Crofelemer for |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |
Crofelemer Product is an investigational small molecule being developed for Short Bowel Syndrome, a gastrointestinal condition. It is currently in early Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in an open-label pilot trial in the United States.
Crofelemer Product is being developed by Jaguar Health, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JAGX. The company is conducting an early Phase 1 clinical trial of the drug in patients with Short Bowel Syndrome.
Crofelemer Product is in early Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing trial is an open-label pilot study with a planned enrollment of 6 participants, and it is currently recruiting patients in the United States.
Crofelemer Product is being studied in one active clinical trial, NCT06326645, titled 'Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome.' This early Phase 1 trial is recruiting 6 adult patients in the United States and is not randomized or blinded.
Yes, Crofelemer Product is also known as Crofelemer Oral Product. Both names refer to the same investigational drug being developed by Jaguar Health, Inc. for Short Bowel Syndrome. The drug is currently in early Phase 1 clinical trials.